Enzalutamide as a Fourth- or Fifth-Line Treatment Option for Metastatic Castration-Resistant Prostate Cancer

Badrising, S.K.; Noort, V. van der; Hamberg, P.; Coenen, J.L.L.M.; Aarts, M.J.; Oort, I.M. van; ... ; Dutch Uro-Oncol Study Grp DUOS (2016)

Article / Letter to editor

• Cross-resistance
• Treatment sequence
• Heavily pretreated patients
• Time interval
• Docetaxel
• Abiraterone
• Cabazitaxel
• Radium-223

• All authors: Badrising, S.K.; Noort, V. van der; Hamberg, P.; Coenen, J.L.L.M.; Aarts, M.J.; Oort, I.M. van; Eertwegh, A.J.M. van den; M. los; Berg, H.P. van den; Gelderblom, H.; Vrijaldenhoven, S.; Kerver, E.D.; Voorthuizen, T. van; Jong, I.J. de; Haanen, J.B.; Bergman, A.M.; Dutch Uro-Oncol Study Grp DUOS
• Date: 2016-12-31
• Journal: Oncology
• Volume: 91
• Issue: 5
• Pages: 267 - 273
• DOI: doi:10.1159/000448219